Research Methods and New Advances in Drug-Drug Interactions Mediated by Renal Transporters

被引:5
|
作者
Lin, Kexin [1 ]
Kong, Xiaorui [1 ]
Tao, Xufeng [1 ]
Zhai, Xiaohan [1 ]
Lv, Linlin [1 ]
Dong, Deshi [1 ]
Yang, Shilei [1 ]
Zhu, Yanna [1 ]
机构
[1] Dalian Med Univ, Dept Pharm, Affiliated Hosp 1, Dalian 116011, Peoples R China
来源
MOLECULES | 2023年 / 28卷 / 13期
基金
中国国家自然科学基金;
关键词
renal transporter; drug-drug interactions; analytical tools; model; ORGANIC ANION TRANSPORTERS; TRANSFECTED MDCK CELLS; CATION TRANSPORTERS; P-GLYCOPROTEIN; ENDOGENOUS PROBE; DOWN-REGULATION; IN-VITRO; PHARMACOKINETIC INTERACTION; RESISTANCE PROTEIN; TUBULAR SECRETION;
D O I
10.3390/molecules28135252
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The kidney is critical in the human body's excretion of drugs and their metabolites. Renal transporters participate in actively secreting substances from the proximal tubular cells and reabsorbing them in the distal renal tubules. They can affect the clearance rates (CLr) of drugs and their metabolites, eventually influence the clinical efficiency and side effects of drugs, and may produce drug-drug interactions (DDIs) of clinical significance. Renal transporters and renal transporter-mediated DDIs have also been studied by many researchers. In this article, the main types of in vitro research models used for the study of renal transporter-mediated DDIs are membrane-based assays, cell-based assays, and the renal slice uptake model. In vivo research models include animal experiments, gene knockout animal models, positron emission tomography (PET) technology, and studies on human beings. In addition, in vitro-in vivo extrapolation (IVIVE), ex vivo kidney perfusion (EVKP) models, and, more recently, biomarker methods and in silico models are included. This article reviews the traditional research methods of renal transporter-mediated DDIs, updates the recent progress in the development of the methods, and then classifies and summarizes the advantages and disadvantages of each method. Through the sorting work conducted in this paper, it will be convenient for researchers at different learning stages to choose the best method for their own research based on their own subject's situation when they are going to study DDIs mediated by renal transporters.
引用
收藏
页数:23
相关论文
共 50 条
  • [1] The Potential Drug-Drug Interactions of Ginkgolide B Mediated by Renal Transporters
    Qiu, Zhixia
    Wang, Lei
    Dai, Yu
    Ren, Weichao
    Jiang, Wenwen
    Chen, Xijing
    Li, Ning
    PHYTOTHERAPY RESEARCH, 2015, 29 (05) : 662 - 667
  • [2] Renal drug transporters and their significance in drug-drug interactions
    Yin, Jia
    Wang, Joanne
    ACTA PHARMACEUTICA SINICA B, 2016, 6 (05) : 363 - 373
  • [3] Renal organic anion transporters in drug-drug interactions and diseases
    Huo, Xiaokui
    Liu, Kexin
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 112 : 8 - 19
  • [4] HOW IMPORTANT ARE TRANSPORTERS IN DRUG-DRUG INTERACTIONS?
    Fromm, M. F.
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2009, 105 : 2 - 3
  • [5] Utilising Endogenous Biomarkers in Drug Development to Streamline the Assessment of Drug-Drug Interactions Mediated by Renal Transporters: A Pharmaceutical Industry Perspective
    Choi, Hee Jae
    Madari, Shilpa
    Huang, Fenglei
    CLINICAL PHARMACOKINETICS, 2024, 63 (06) : 735 - 749
  • [7] Renal Drug Transporters and Drug Interactions
    Ivanyuk, Anton
    Livio, Francoise
    Biollaz, Jerome
    Buclin, Thierry
    CLINICAL PHARMACOKINETICS, 2017, 56 (08) : 825 - 892
  • [8] Renal Drug Transporters and Drug Interactions
    Anton Ivanyuk
    Françoise Livio
    Jérôme Biollaz
    Thierry Buclin
    Clinical Pharmacokinetics, 2017, 56 : 825 - 892
  • [9] Pharmacokinetic and Pharmacodynamic Drug-Drug Interactions: Research Methods and Applications
    Sun, Lei
    Mi, Kun
    Hou, Yixuan
    Hui, Tianyi
    Zhang, Lan
    Tao, Yanfei
    Liu, Zhenli
    Huang, Lingli
    METABOLITES, 2023, 13 (08)
  • [10] ABC TRANSPORTERS: THEIR RELATIONSHIP TO ILLNESSES AND DRUG-DRUG INTERACTIONS
    Aszalos, Adorjan
    ANTICANCER RESEARCH, 2004, 24 (5D) : 3425 - 3425